Acute Phase Inflammatory Proteins, Gut Microbiota Dysbiosis and Severity of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus (original) (raw)

Abstract

Since obesity and type 2 diabetes mellitus (DM) became almost pandemic, incidence and prevalence of associated nonalcoholic fatty liver disease (NAFLD) rose accordingly. Aim of the study was assessing whether there is a link between circulating C-reactive protein(CRP), gut microbiota dysbiosis and severity of liver disease in patients with NAFLD and confirmed type 2 DM. 50 patients diagnosed with type 2 DM were consecutively enrolled in this cross-sectional, pilot study, being evenly divided in two groups, as matched pairs, on the basis of presence or absence of NAFLD confirmed by abdominal and CT exam, after ruling out a lot of diseases and conditions. Patients underwent measurements of waist circumference, blood pressure (BP), body mass index (BMI) and thoroughly physical examination. Complete blood count (CBC), liver tests, CRP, fasting plasma glucose (FPG), low density lipoprotein(LDL) and high-density lipoprotein(HDL) cholesterol, triglycerides, creatinin and uric acid, micro p...

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (31)

  1. WILLIAMS CD, STENGEL J, ASIKE MI et al. Prevalence of NAFLD and NASH among a largely middle -aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140, 2011, p.124
  2. CHASALANI N, YOUNOSSI Z, LANVINE JE et al. The diagnostic and management of NAFLD: Practice guidance from AASLD. Hepatology 67, 2018, p.328
  3. PERUMPAIL BJ,KHAN MA,YOO ER et al. Clinical epidemiology and disease burden of NAFLD World J Gastroenterol 23, no.47,2017, p.8263
  4. GEORGESCU D, COCEALA L, BASA N et al. Ultrasound in the assessment of fatty liver in patients with metabolic syndrome Ultraschall in der Medizin. S29, 2008, S6.
  5. HERNAEZ R, LAZO R, BONEKAMP S et al. Diagnostic accuracy and reliability of ultra- sonography for the detection of fatty liver: a meta-analysis. Hepatology 54, 2011, p.1082
  6. SIMA A, SPOREA I, TIMAR R et al. Noninvasive assessment of liver steatosis and fibrosis using TE and controlled attenuation parameter in type 2 diabetes patients. Acta Endocrinologica, 14, no.3, 2018,p.394
  7. STINE JG, SHAH NL, ARGO CK, et al. Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis. Liver Transpl. 21,2015,p.1016
  8. GEORGESCU D, IURCIUC M, IONITA I et al. Portal vein thrombosis and gut microbiota: understanding the burdem. Rev. Chim., 70, (6), 2019, 2181
  9. BUZZETTI E, PINZANI M,TSOCHATZIS EA The multiple-hit pathogenesis of NAFLD Metabolism. 65,2016,p.1038
  10. LEUNG C, RIVERA L, FURNESS JB,ANGUS PW. The role of gut microbiota in NAFLD.Nat Rev Gastroenterol and Hepatol. 13, no.7, 2016, p.412
  11. SANDRIN TR, GOLDSTEIN JE and SHOEMAKER S. MALDI TOF MS profiling of bacteria at the strain level: A review. Mass Spectrometry Reviews 32, no.3, 2013, p.188
  12. WU I, POTEMPA LA, EL KEBIR D, FILEP JG. C-reactive protein and inflammation, Biol Chem 396, 2015, p.1181
  13. LI Q, DHYANI M, GRAJO JR, et al. Current status of imaging in NAFLD. World J Hepatol 10, no.8, 2018, p.530
  14. MORRA R, MUNTEANU M, IMBERT-BISMUT F et al. Fibromax: towards a new universal biomarker of liver disease? Expert Rev Mol Diagn 7, 2007, p.5
  15. BEGOGNI G, BELLENTANI S, MIGLIOLI L et al. The fatty liver index: a simple and accurate prediction of hepatic steatosis in general population. BMJ Gastroenterol. 6, no.1, 2006, p.33
  16. ***Diagnostic and classification of diabetes mellitus. American Diabetes Association .Diabetes Care 33, suppl1, 2010, p.32
  17. FRITH J, DAY CP, HENDERSON E, BURT AD, NEWTON JL. NAFLD in older people.Gerontology 55, 2009, p.607
  18. KOEHLER EM, SCHOUTEN JN, HANSEN BE et al. External validation of the fatty liver index for identifying NAFLD in a population-based study. Clin Gastroenterol Hepatol 11, 2013, p.1201
  19. KOTHARI S, DHAMI-SHAH H, SHAH SR ,Antidiabetic drugs and statins in NAFLD.J Clin Experim Hepatol. 9,no. 6,2019,p.723
  20. ZHANG QQ, LU LG.Nonalcoholic fatty liver disease: dyslipidemia, risk for cardio-vascular complications and treatment strategy. J Clin Transl Hepatol.3, no.1, 2015, p.78
  21. FESTI D, SCHIUMRINI R, EUSEBI LH et al. Gut microbiota and metabolic syndrome World J Gastroenterol 20, no.43, 2014, p.16079 https://doi.org/10.37358/Rev. Chim.1949
  22. Rev. Chim., 71 (5), 2020, 290-298 298 https://doi.org/10.37358/RC.20.5.8136
  23. FORSLUND K, HILDEBRAND F, NIELSEN T et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota.Nature. 528, no.7581, 2015, p.262
  24. SALZMAN ET,PALACIOS T,THOMSEN M,VITETTA L.Intestinal microbiome shifts, dysbiosis, inflammation and nonalcoholic fatty liver disease.Front Microbiol 9, 2018, p.61
  25. JIN M, QIAN Z,YIN J,XU V,ZHOU X.J. The role of intestinal microbiota in cardio-vascular disease. Cell Mol Med. 23. No.4, 2019, p.2343
  26. WIJAMPREECHA K, THONGPRAYOON C, BOONPHENG B et al. NAFLD and albuminuria: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 30, no.9, 2018,p.986
  27. BELIZARIO JE, FAINTUCH J, GARAY-MALPARTIDA M. Gut microbiome dysbiosis and immunometabolism: new frontiers for treatment of metabolic diseases. Hindawi. Mediators of Inflammation. 2018, p.2037838
  28. REID G, YOUNES JA, VAN DER MEI HC et al. Microbiota restoration: natural and supplemented recovery of human microbial communities. Nat Rev Microbiol. 9, no.1,2011, p.27
  29. ISAIA IA, IENASCU IMC, ANDRICA FM et al. Preliminary in vitro evaluation of seven different plant extracts on A375, B1664A5 and HaCat cell lines. Rev. Chim., 67, (8), 2016, 1633
  30. NICOLOV M, DUSE AO, GEORGESCU D et al. Preliminary studies on betulinic acid crystals with organic solvents. Rev. Chim., 87, (7), 2016, 1411
  31. JURCA-SIMINA IE, JUGANARU I, IURCIUC MS et al. What if body fat percentage association with FINDRISC score leads to a better prediction of type 2 diabetes mellitus?Rom J Morphol Embryol 60, no.1, 2019, p.205 Manuscript received: 20.02.2020